Correction to: Nature Medicine https://doi.org/10.1038/s41591-022-02102-9. Published online 15 December 2022.
In the version of this article initially published, there was an error in the abstract, where in the sentence now reading, in part, “In participants with HFimpEF… first worsening heart failure events (HR = 0.84),” the hazard ratio originally read “0.78,” while in the second paragraph of the “Outcomes by HFimpEF status” Results subsection, in the sentence now reading, in part, “The effect of dapagliflozin on HF outcomes was also similar in those with HFimpEF (HR = 0.84, 95% CI = 0.61–1.14) and those with LVEF consistently over 40% (HR = 0.78),” the hazard ratio values were mistakenly interchanged. The values have been updated in the HTML and PDF versions of the article.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Vardeny, O., Fang, J.C., Desai, A.S. et al. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nat Med (2023). https://doi.org/10.1038/s41591-023-02302-x